Loading...
01/11 03:14
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows mixed signals: strong cash position and potential for AMT-130, but increased expenses and uncertain regulatory outcomes. The Q&A reveals robust testing and a motivated community for Huntington's, but concerns about dose toxicity and unclear FDA interactions. The strategic plan indicates optimism for future approvals, but the lack of EMA/MHRA engagement and management's evasiveness on key questions temper expectations. Overall, the neutral sentiment reflects positive long-term prospects but short-term uncertainties.
Revenue for Q3 2025 $3.7 million, an increase of $1.4 million (approximately 60.87%) year-over-year. The increase was driven by a $1.5 million rise in license revenues, partially offset by a $0.1 million decrease in collaboration revenues.
Cost of contract manufacturing revenues for Q3 2025 $0, compared to $0.8 million in Q3 2024. This change is due to the divestment of the Lexington facility in July 2024, which led to these costs being recorded net of revenue within other expenses.
Research and development expenses for Q3 2025 $34.4 million, an increase of $3.8 million (approximately 12.42%) year-over-year. The increase was driven by a $10.1 million rise in direct R&D expenses, including $6.6 million related to preparation for the BLA submission of AMT-130, offset by decreases of $3.4 million in severance costs and $3 million in costs related to disposables, facilities, and other expenses.
Selling, general and administrative expenses for Q3 2025 $19.4 million, an increase of $7.8 million (approximately 67.24%) year-over-year. This was primarily due to a $2.4 million rise in employee-related expenses and a $4.9 million increase in professional fees, including $3 million for potential commercialization of AMT-130 in the U.S.
Cash, cash equivalents, and investment securities as of September 30, 2025 $694.2 million, an increase of $326.7 million (approximately 88.88%) from $367.5 million as of December 31, 2024. The increase was primarily due to net proceeds of $404.2 million from public offerings in 2025.
AMT-130 for Huntington's disease: Positive top-line data from Phase I/II study showed a 75% slowing of disease progression at 3 years (cUHDRS) and 60% slowing (total functional capacity). However, FDA feedback has introduced uncertainty regarding BLA submission.
AMT-260 for mesial temporal lobe epilepsy: Initial data showed promising reduction in seizure frequency over 5 months with no serious adverse events. Recruitment expanded to a second cohort at a higher dose.
AMT-191 for Fabry disease: Phase I/IIa trial showed supraphysiological alpha-Gal A enzyme activity, stable plasma lyso-Gb3 levels, and manageable safety profile. Patients successfully withdrawn from enzyme replacement therapy.
AMT-162 for SOD1 ALS: Enrollment paused due to dose-limiting toxicity observed in one patient. Data collection continues.
U.S. market preparation for AMT-130: Focus on stakeholder engagement, including treatment centers, payers, and patient advocacy groups. Planning for potential launch.
Expansion to EU and UK markets: Exploring additional potential markets for AMT-130 outside the U.S.
Financial performance: Revenue increased to $3.7 million in Q3 2025 from $2.3 million in Q3 2024. Cash reserves at $694.2 million, sufficient to fund operations into 2029.
R&D and administrative expenses: R&D expenses rose to $34.4 million, driven by BLA preparation for AMT-130. Administrative expenses increased to $19.4 million due to commercialization efforts.
Regulatory strategy for AMT-130: Engaging with FDA to clarify next steps after unexpected feedback. Planning to advance discussions with EU and UK regulatory agencies.
FDA Feedback on AMT-130: The FDA no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control may be adequate to support a BLA submission. This unexpected feedback introduces uncertainty into the regulatory approval timeline for AMT-130, potentially delaying its availability to patients.
AMT-162 for SOD1 ALS: Enrollment in the Phase I/II EPISOD1 trial of AMT-162 has been voluntarily paused due to a dose-limiting toxicity observed in one patient, resulting in a serious adverse event. This raises concerns about the safety profile of AMT-162 and its future development.
Increased R&D and SG&A Expenses: Research and development expenses increased by $3.8 million, and selling, general, and administrative expenses rose by $7.8 million compared to the same period in 2024. These rising costs, particularly related to the preparation for the BLA submission and potential commercialization of AMT-130, could strain financial resources if revenue growth does not keep pace.
Regulatory and Market Uncertainty for AMT-130: The uncertainty surrounding the FDA's approval process for AMT-130 and the need to engage with other regulatory agencies in the EU and UK could delay market entry and impact the company's strategic plans.
Paused Enrollment in AMT-162 Trial: The pause in enrollment for AMT-162 due to safety concerns may delay the program's progress and affect investor confidence in the company's pipeline.
AMT-130 for Huntington's Disease: The company plans to urgently engage with the FDA to discuss next steps for the BLA submission for AMT-130. They expect to receive formal meeting minutes from the FDA within 30 days. The company remains committed to working collaboratively with the FDA to bring AMT-130 to patients in the U.S. as rapidly as possible. Additionally, they are planning to advance discussions with regulatory agencies in the EU and the U.K. for potential market launches outside the U.S.
AMT-260 for Mesial Temporal Lobe Epilepsy: The company has activated 17 recruiting sites in the U.S. and completed enrollment of the first 3 patients in the first cohort. Recruitment has expanded to include mesial temporal lobe epilepsy in the dominant hemisphere, and a second cohort at a higher dose has been initiated. Updated data from the study is expected in the first half of 2026.
AMT-191 for Fabry Disease: Enrollment in the second lower dose cohort has been completed, and a third cohort is currently enrolling. Updated data from the ongoing Phase I/IIa trial is expected in the first half of 2026.
AMT-162 for SOD1 ALS: Enrollment in the Phase I/II EPISOD1 trial has been voluntarily paused following a serious adverse event in one patient. The company will continue to collect and evaluate data from treated patients.
The selected topic was not discussed during the call.
The earnings call shows mixed signals: strong cash position and potential for AMT-130, but increased expenses and uncertain regulatory outcomes. The Q&A reveals robust testing and a motivated community for Huntington's, but concerns about dose toxicity and unclear FDA interactions. The strategic plan indicates optimism for future approvals, but the lack of EMA/MHRA engagement and management's evasiveness on key questions temper expectations. Overall, the neutral sentiment reflects positive long-term prospects but short-term uncertainties.
The earnings call summary shows mixed signals. The basic financial performance is weak due to a significant revenue decline, but the company maintains a strong cash position. Product development is promising with advanced pipeline stages and FDA breakthrough designation. Market strategy and shareholder return plans are unclear or not emphasized. The Q&A reveals optimism in regulatory and commercial prospects but lacks clarity on key metrics like NfL. Given these mixed factors, the stock is likely to remain stable in the short term, leading to a neutral prediction.
The earnings call highlights significant revenue decline and supply chain challenges, despite cost reductions and a strong cash position. The Q&A reveals cautious optimism but also regulatory uncertainties and unresolved serious adverse events. The completion of a follow-on offering could dilute shares, further impacting sentiment. While some positive aspects exist, the overall sentiment leans negative due to financial underperformance and regulatory uncertainties.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
